Clinical trial · Interventional
Clinical Outcomes of Indocyanine Green Tracer Using in Laparoscopic Gastrectomy With Lymph Node Dissection for Remnant Gastric Cancer
NCT05618821CI-TRIAL-00062210recruitingPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Patients with resectable remnant gastric cancer were selected as study subjects to investigate the safety, efficacy, and feasibility of ICG near-infrared imaging tracing in guiding laparoscopic lymph node dissection for remnant gastric cancer by comparing injection ICG group and non-injection ICG group.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Gastric Cancer | Malignant Gastric Neoplasm | CURATED_BROADER | 0.80 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Indocyanine Green Tracer | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- ICG
- description
- Laparoscopic gastrectomy Group with the use of near-infrared imaging (ICG group)
- interventionNames
- Drug: Indocyanine Green Tracer
- type
- ACTIVE_COMPARATOR
- label
- Non-ICG
- description
- Laparoscopic gastrectomy Group without the use of near-infrared imaging (Non-ICG group)
- interventionNames
- Drug: Indocyanine Green Tracer
Primary outcomes (1)
- measure
- Total Number of Retrieved Lymph Nodes
- timeFrame
- 30 days
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 75 Years
Show eligibility criteria text
Inclusion Criteria: 1. Age from 18 to 75 years 2. Remnant gastric cancer (cT1-4a, N-/+, M0 at preoperative evaluation according to the American Joint Committee on Cancer (AJCC) Cancer Staging Manual Seventh Edition) (4) No distant metastasis, no direct invasion of pancreas, spleen or other organs nearby in the preoperative examinations (5) Performance status of 0 or 1 on the ECOG (Eastern Cooperative Oncology Group) scale (6) ASA (American Society of Anesthesiology) class I to III (7) Written informed consent Exclusion Criteria: 1. Women during pregnancy or breast-feeding 2. Severe mental disorder 3. History of previous upper abdominal surgery (except for laparoscopic cholecystectomy and gastrectomy) 4. History of previous gastric surgery (including ESD/EMR for gastric cancer) 5. Rejection of laparoscopic resection 6. History of allergy to iodine agents 7. Enlarged or bulky regional lymph node diameter over 3cm by preoperative imaging 8. History of other malignant disease within past five years 9. History of previous neoadjuvant chemotherapy or radiotherapy 10. History of unstable angina or myocardial infarction within the past six months 11. History of unstable angina or myocardial infarction within past six months 12. History of continuous systematic administration of corticosteroids within one month 13. Requirement of simultaneous surgery for another disease 14. Emergency surgery due to complications (bleeding, obstruction or perforation) caused by gastric cancer 15. FEV1\<50% of the predicted values 16. Linitis plastica, Widespread
References
Publications (0)
Data not yet available
No reference posted for this study.